YAOTANG BIOLOGY
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.
YAOTANG BIOLOGY
Social Links:
Industry:
Biopharma Biotechnology
Founded:
2021-07-01
Address:
Minhang, Shanghai, China
Country:
China
Website Url:
http://www.yoltx.com
Status:
Active
Contact:
1-215-226-0086
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
SPF HiChina DNS Alibaba Cloud MailBox
Investors List
Xianfeng Qiyun
Xianfeng Qiyun investment in Angel Round - Yaotang Biology
Official Site Inspections
http://www.yoltx.com
- Host name: 106.15.103.126
- IP address: 106.15.103.126
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Yaotang Biology"
ABOUT YolTech - yoltx.com
YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines.See details»
YolTech
YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver …See details»
Yaotang Biology - Crunchbase Company Profile & Funding
Organization. Yaotang Biology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Yaotang Bio is a biotechnology …See details»
LATESTNEWS - yoltx.com
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major …See details»
YolTech Therapeutics Company Profile 2024: Valuation, …
YolTech Therapeutics General Information Description. Developers of gene editing tools and gene editing drugs designed to improve disease treatment efficiency. The company's drugs are focused on the optimization of CRISPR …See details»
Investors-YolTech - yoltx.com
12F, Building A, No.58 Tanzhu Road, Minhang District, Shanghai,China. Linkedin. 021-52260086See details»
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Mar 4, 2024 YOLT-201 leads the first clinical approval of an in vivo gene editing drug mediated by lipid nanoparticles (LNP) in China.This breakthrough will further promote research and …See details»
yoltx.com - Company Profile - Tracxn
Jan 2, 2024 yoltx.com - Developer of mRNA and gene editing drugs for multiple diseases. Raised a total funding of $14.1M over 3 rounds from 4 investors. Founded by Yuxuan Wu in …See details»
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the …See details»
YolTech Therapeutics Administers First Patient Dose in IIT
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major …See details»
YolTech Therapeutics Receives U.S. FDA Rare Pediatric ... - BioSpace
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering gene editing company focused on developing in vivo gene editing medicines, today announced that the …See details»
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Shanghai, China, March 1, 2024 - YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug …See details»
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment …
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate …See details»
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment …
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate …See details»
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT …
SHANGHAI, China I August 22, 2024 I YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: …See details»
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug ...See details»
YolTech Receives U.S. FDA ODD for YOLT-203 in Treating PH1
Sep 23, 2024 With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company …See details»
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT …
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major …See details»
First Patient Dosed in Clinical Trial of YOLT-201 for the ... - BioSpace
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate …See details»
YolTech Therapeutics Receives U.S. FDA Rare Pediatric Disease ...
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering gene editing company focused on developing in vivo gene editing medicines, today announced that the …See details»